Abituzumab Combined with Cetuximab Plus Irinotecan Versus Cetuximab Plus Irinotecan Alone, as Second-Line Treatment for Patients with KRAS Wild-Type Metastatic Colorectal Cancer: The Poseidon Phase I/Randomized Phase II Trial

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Annals of Oncology ◽

10.1016/s0923-7534(21)00330-6 ◽

2016 ◽

Vol 27 ◽

pp. ix54

Author(s):

T. Ando ◽

S. Yuki ◽

H. Nakatsumi ◽

T. Muranaka ◽

A. Hosokawa ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Final Analysis ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Analysis Phase ◽

Administration Interval

Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)

Annals of Oncology ◽

10.1093/annonc/mdy281.154 ◽

2018 ◽

Vol 29 ◽

pp. viii202

Author(s):

A. De Stefano ◽

G. Nasti ◽

A. Febbraro ◽

G. Rosati ◽

F. Giuliani ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽

2049 AIO-KRK-0109: A randomized phase II trial of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as 1st-line treatment in RAS-wild-type metastatic colorectal cancer (mCRC)

European Journal of Cancer ◽

10.1016/s0959-8049(16)30972-8 ◽

2015 ◽

Vol 51 ◽

pp. S344-S345 ◽

Cited By ~ 1

Author(s):

U.M. Martens ◽

S. Wessendorf ◽

J. Riera Knorrenschild ◽

P. Buechner-Steudel ◽

A. Florschuetz ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

SPIRITT: A multicenter, open-label, randomized, phase II clinical trial evaluating safety and efficacy of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with metastatic colorectal cancer (mCRC) with wild-type KRAS tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps195 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS195-TPS195

Author(s):

A. L. Cohn ◽

K. Krishnan ◽

J. R. Hecht

Keyword(s):

Colorectal Cancer ◽

Clinical Trial ◽

Phase Ii ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Open Label ◽

Safety And Efficacy ◽

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Annals of Oncology ◽

10.1093/annonc/mdw581.004 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Author(s):

T. Ando ◽

S. Yuki ◽

H. Nakatsumi ◽

T. Muranaka ◽

A. Hosokawa ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Final Analysis ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Analysis Phase ◽

Administration Interval

Randomized Phase Ii Trial of Hange-Shasin-To Versus Placebo to Prevent Diarrhea in Patients with Metastatic Colorectal Cancer Under Iris+Bev Second-Line Treatment (Hgcsg1301)

Annals of Oncology ◽

10.1093/annonc/mdu356.73 ◽

2014 ◽

Vol 25 ◽

pp. iv541

Author(s):

H. Fukushima ◽

S. Yuki ◽

H. Nakatsumi ◽

H. Hayashi ◽

K. Harada ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

416P Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.937 ◽

2021 ◽

Vol 32 ◽

pp. S543

Author(s):

J. Aparicio ◽

A.C. Virgili Manrique ◽

J. Capdevila ◽

F. Muñoz Boza ◽

P. Galván ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Second Line ◽

Wild Type ◽

First Line ◽

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense ◽

Faculty Opinions recommendation of FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717997102.793478384 ◽

2013 ◽

Author(s):

Sabine Tejpar ◽

Loredana Vecchione

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study

Annals of Oncology ◽

10.1093/annonc/mdt116 ◽

2013 ◽

Vol 24 (7) ◽

pp. 1769-1777 ◽

Cited By ~ 27

Author(s):

T. Brodowicz ◽

T.E. Ciuleanu ◽

D. Radosavljevic ◽

E. Shacham-Shmueli ◽

D. Vrbanec ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽